EXMceuticals Inc. becomes member of the Portuguese Association of the Pharmaceutical Industry (APIFARMA).
29 September 2020 - 3:00PM
EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (OTCQB:EXM…,
(the "Company" or "EXM"), an emerging bio-sciences company
specializing in the production of unique cannabinoid formulations,
is pleased to announce its membership to The Portuguese Association
of the Pharmaceutical Industry – APIFARMA.
After an extensive diligence period, EXMceuticals
Portugal has been accepted to become a member of the Portuguese
Association of the Pharmaceutical Industry (APIFARMA). EXM’s
interests will now be represented by an Association that brings
together industry, development initiatives and the broader health
community. The Association helps to nurture innovation, promote
resilient regulatory systems, maintain high standards of quality,
uphold ethical practices and advocate sustainable health policies
to meet patient and health system needs. This is timely as the
Portuguese government has designated the broader health sciences
industry to be one of national strategic focus, as well as a
priority for the economic rebuild and planned re-industrialisation
post-COVID 19.
“We are obviously thrilled to become a member of
APIFARMA,” commented Jonathan Summers, EXM’s CEO, “and this
underlines the huge amount of work the operational team in Portugal
has done as well as the significant changes and advancements the
company has made in recent months. In late 2019 the decision was
made to cancel our plans for in-house cannabis cultivation, and to
focus activities solely in Portugal on R&D, extraction,
purification, refining and formulation. This news, and the recent
landmark grant for COVID research from the European Union, are real
milestones on our journey of our transformation to a pure
bio-sciences company.”
Founded in 1975, APIFARMA represents more than 120
companies operating in Portugal and is responsible for the
production and import of drugs for human and veterinary use,
serums, vaccines, active substances for use in medicines and in
vitro diagnostics. APIFARMA’s mission is to encourage the
development of new therapies that respond to the evolving needs of
patients and prevent new pathologies, as well as making new
medicines available that continually improve health and quality of
life. Through APIFARMA, the Portuguese Pharmaceutical Industry
upholds the highest ethical and quality standards in addition to
promoting social responsibility and the solidarity of the industry.
APIFARMA's also defends and promotes the interests of its members,
covering all relevant areas of activity from R&D to
production.
ON BEHALF OF THE BOARD OF DIRECTORS OF
EXMCEUTICALS INC.
Jonathan Summers, Chairman and Chief Executive
OfficerFor further information, contact: Investor Relations Email:
investors@exmceuticals.com
Media Enquiries:Email: media@exmceuticals.com
FOR MORE UPDATES ON THE
COMPANY
Follow us on Twitter:
https://twitter.com/EXMceuticalsFollow us on LinkedIn:
https://www.linkedin.com/company/exmceuticalsinc/
ABOUT EXMCEUTICALS
EXM's core activities are centred around the
strategic matching of natural bioactive ingredients extracted from
the cannabis plant with the needs of the nutraceutical,
cosmeceutical, and therapeutic industries. EXMceuticals Portugal,
obtained from INFARMED in November 2019, possesses unique
authorization for cannabis importation and research and development
at its specially equipped laboratory in Lisbon, Portugal. EXM's
team comprises highly qualified scientific and management
professionals covering all areas demanded by the cannabis industry
- organic and analytical chemistry, biology, biochemistry,
genetics, compliance, IP, partnerships, and legal and regulatory
issues.
EXM is in the final stages of detailed planning for
an industrial-scale pharmaceutical standard facility in Portugal
which will complement its existing R&D lab and pilot refinery.
An existing property has been secured in Setubal, south of Lisbon,
which requires retro-fitting to EU-GMP / API standards. Once
complete, the facility will contain extraction, purification, and
refining capabilities, as well as a Q&A laboratory. Once built,
we believe the Setubal facility will be the largest cannabinoids
and terpenes extraction, purification, and refining facility in the
European Union.
The refinery will be able to process cannabis
biomass, extracts, and distillates from Portugal, as well as from
international sources where the regulatory import requirements of
INFARMED have been met. EXM has multiple MOU's in place which will
ensure the refinery can be operated to initial capacity from day 1
and then scaled further. This refinery, once licensed, will
distribute medical cannabis ingredients on a B2B basis, to produce
API's and cannabis-based compounds in a reliable, consistent, and
standardized process. EXM targets and maintains the highest
certification standards to meet the needs of the pharmaceutical,
nutraceutical, and cosmetic industries worldwide.
CSE:
EXM| FSE:
A2PAW2
Neither the CSE nor the FSE has approved nor
disapproved of the contents of this news release. Neither the CSE
nor the FSE accepts responsibility for the adequacy or accuracy of
this release.
Certain information contained herein may constitute
"forward-looking information" under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as, "will
be", "expected", "proposes", "intends" or variations of such words
and phrases or statements that certain actions, events or results
"will" occur. Forward-looking statements regarding the Company's
business operations, the extraction of cannabis ingredients and the
exportation of the extracts, the results of testing at our
facilities established for the European market, future laws and
regulations governing the sale of our products in Europe and
elsewhere, and the potential to generate sales, and completion of a
Qualifying Financing, are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of EXM to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information. There
can be no assurance that such statements will prove to be accurate,
as actual results and future events could differ materially from
those anticipated in such statements. Accordingly, readers should
not place undue reliance on forward-looking statements and
forward-looking information. EXM will not update any
forward-looking statements or forward-looking information that is
incorporated by reference herein, except as required by applicable
securities laws.
EXMceuticals (CSE:EXM)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
EXMceuticals (CSE:EXM)
Historical Stock Chart
Von Dez 2023 bis Dez 2024